<DOC>
	<DOCNO>NCT01847794</DOCNO>
	<brief_summary>To identify correlation HER2 expression tissue peripheral CTC . identify HER2 expression CTCs clinical prognosis advanced/metastatic gastric cancer . Confirm presence CTCs sensitive monitoring response chemotherapy .</brief_summary>
	<brief_title>HER2 Positive CTC Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Having sign informed consent Age≥ 18 year old HER2 overexpression confirm IHC ISH ( IHC 3+ , IHC2+/ISH+ ) Histologically confirm gastric adenocarcinoma Unresectable recurrent metastatic disease Previous neoadjuvant adjuvant treatment gastric cancer , applicable , 6 month Measurable disease accord RECIST criterion Karnofsky performance status ≥70 Life expectancy ≥3 month No prior radiotherapy except radiotherapy nontarget lesion study 4 week ALT AST &lt; 2.5 time ULN ( ≤5 time ULN patient liver metastasis ) Serum albumin level ≥3.0g/dL Serum AKP &lt; 2.5 time ULN Serum creatinine &lt; ULN , CCr &lt; 60ml/min Bilirubin level &lt; 1.5 ULN WBC &gt; 3,000/mm3 , absolute neutrophil count ≥2000/mm3 , platelet &gt; 100,000/mm3 , Hb &gt; 9g/dl Previous systemic therapy metastatic gastric cancer Surgery ( exclude diagnostic biopsy ) within 4 week prior study entry Contraindications nuclear magnetic resonance image fitment cardiac pacemaker , nerve stimulator , aneurysm clip , metallic foreign body eye ball . Allergic constitution allergic history protium biologic product investigate agent . Severe heart disease history record congestive heart failure , uncontrolled cardiac arrhythmia , angina pectoris need medication , cardiac valve disease , severe abnormal ECG finding , cardiac infarction , retractable hypertension . Pregnancy lactation period Other previous malignancy within 5 year , except nonmelanoma skin cancer Legal incapacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>